Note: On April 30, 2024, the Federal mandate for COVID-19 and influenza associated hospitalization data to be reported to CDC’s National Healthcare Safety Network (NHSN) expired. Hospitalization data beyond April 30, 2024, will not be updated on the Open Data Portal. Hospitalization and ICU admission data collected from summer 2020 to May 10, 2023, are sourced from the California Hospital Association (CHA) Survey. Data collected on or after May 11, 2023, are sourced from CDC's National Healthcare Safety Network (NHSN).

Data is from the California Department of Public Health (CDPH) Respiratory Virus State Dashboard at https://www.cdph.ca.gov/Programs/CID/DCDC/Pages/Respiratory-Viruses/RespiratoryDashboard.aspx.

Data are updated each Friday around 2 pm.

For COVID-19 death data: As of January 1, 2023, data was sourced from the California Department of Public Health, California Comprehensive Death File (Dynamic), 2023–Present. Prior to January 1, 2023, death data was sourced from the COVID-19 case registry. The change in data source occurred in July 2023 and was applied retroactively to all 2023 data to provide a consistent source of death data for the year of 2023. Influenza death data was sourced from the California Department of Public Health, California Comprehensive Death File (Dynamic), 2020–Present.

COVID-19 testing data represent data received by CDPH through electronic laboratory reporting of test results for COVID-19 among residents of California. Testing date is the date the test was administered, and tests have a 1-day lag (except for the Los Angeles County, which has an additional 7-day lag). Influenza testing data represent data received by CDPH from clinical sentinel laboratories in California. These laboratories report the aggregate number of laboratory-confirmed influenza virus detections and total tests performed on a weekly basis. These data do not represent all influenza testing occurring in California and are available only at the state level.

This dataset represents preliminary estimates of cumulative U.S. COVID-19 disease burden for the 2024-2025 period, including illnesses, outpatient visits, hospitalizations, and deaths. The weekly COVID-19-associated burden estimates are preliminary and based on continuously collected surveillance data from patients hospitalized with laboratory-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. The data come from the Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-NET), a surveillance platform that captures data from hospitals that serve about 10% of the U.S. population. Each week CDC estimates a range (i.e., lower estimate and an upper estimate) of COVID-19 -associated burden that have occurred since October 1, 2024.

Note: Data are preliminary and subject to change as more data become available. Rates for recent COVID-19-associated hospital admissions are subject to reporting delays; as new data are received each week, previous rates are updated accordingly.

References

1. Reed C, Chaves SS, Daily Kirley P, et al. Estimating influenza disease burden from population-based surveillance data in the United States. PLoS One. 2015;10(3):e0118369. https://doi.org/10.1371/journal.pone.0118369 
2. Rolfes, MA, Foppa, IM, Garg, S, et al. Annual estimates of the burden of seasonal influenza in the United States: A tool for strengthening influenza surveillance and preparedness. Influenza Other Respi Viruses. 2018; 12: 132– 137. https://doi.org/10.1111/irv.12486
3. Tokars JI, Rolfes MA, Foppa IM, Reed C. An evaluation and update of methods for estimating the number of influenza cases averted by vaccination in the United States. Vaccine. 2018;36(48):7331-7337. doi:10.1016/j.vaccine.2018.10.026 
4. Collier SA, Deng L, Adam EA, Benedict KM, Beshearse EM, Blackstock AJ, Bruce BB, Derado G, Edens C, Fullerton KE, Gargano JW, Geissler AL, Hall AJ, Havelaar AH, Hill VR, Hoekstra RM, Reddy SC, Scallan E, Stokes EK, Yoder JS, Beach MJ. Estimate of Burden and Direct Healthcare Cost of Infectious Waterborne Disease in the United States. Emerg Infect Dis. 2021 Jan;27(1):140-149. doi: 10.3201/eid2701.190676. PMID: 33350905; PMCID: PMC7774540.
5. Reed C, Kim IK, Singleton JA,  et al. Estimated influenza illnesses and hospitalizations averted by vaccination–United States, 2013-14 influenza season. MMWR Morb Mortal Wkly Rep. 2014 Dec 12;63(49):1151-4. https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6349a2.htm 
6. Reed C, Angulo FJ, Swerdlow DL, et al. Estimates of the Prevalence of Pandemic (H1N1) 2009, United States, April–July 2009. Emerg Infect Dis. 2009;15(12):2004-2007. https://dx.doi.org/10.3201/eid1512.091413  
7. Devine O, Pham H, Gunnels B, et al. Extrapolating Sentinel Surveillance Information to Estimate National COVID-19 Hospital Admission Rates: A Bayesian Modeling Approach. Influenza and Other Respiratory Viruses. https://onlinelibrary.wiley.com/doi/10.1111/irv.70026. Volume18, Issue10. October 2024.
8. https://www.cdc.gov/covid/php/covid-net/index.html">COVID-NET | COVID-19 | CDC 
9. https://www.cdc.gov/covid/hcp/clinical-care/systematic-review-process.html 
10. https://academic.oup.com/pnasnexus/article/1/3/pgac079/6604394?login=false">Excess natural-cause deaths in California by cause and setting: March 2020 through February 2021 | PNAS Nexus | Oxford Academic (oup.com)
11. Kruschke, J. K. 2011. Doing Bayesian data analysis: a tutorial with R and BUGS. Elsevier, Amsterdam, Section 3.3.5.

Background: As of October 2020, COVID-19 has caused 1,000,000 deaths worldwide. However, large-scale studies of COVID-19 mortality and new-onset comorbidity compared to individuals tested negative for COVID-19 and individuals tested for influenza A/B are lacking. We investigated COVID-19 30-day mortality and new-onset comorbidity compared to individuals with negative COVID-19 test results and individuals tested for influenza A/B.Methods and findings: This population-based cohort study utilized electronic health records covering roughly half (n = 2,647,229) of Denmark's population, with nationwide linkage of microbiology test results and death records. All individuals ≥18 years tested for COVID-19 and individuals tested for influenza A/B were followed from 11/2017 to 06/2020. Main outcome was 30-day mortality after a test for either COVID-19 or influenza. Secondary outcomes were major comorbidity diagnoses 30-days after the test for either COVID-19 or influenza A/B. In total, 224,639 individuals were tested for COVID-19. To enhance comparability, we stratified the population for in- and outpatient status at the time of testing. Among inpatients positive for COVID-19, 356 of 1,657 (21%) died within 30 days, which was a 3.0 to 3.1-fold increased 30-day mortality rate, when compared to influenza and COVID-19-negative inpatients (all p < 0.001). For outpatients, 128 of 6,263 (2%) COVID-19-positive patients died within 30 days, which was a 5.5 to 6.9-fold increased mortality rate compared to individuals tested negative for COVID-19 or individuals tested positive or negative for influenza, respectively (all p < 0.001). Compared to hospitalized patients with influenza A/B, new-onset ischemic stroke, diabetes and nephropathy occurred more frequently in inpatients with COVID-19 (all p < 0.05).Conclusions: In this population-based study comparing COVID-19 positive with COVID-19 negative individuals and individuals tested for influenza, COVID-19 was associated with increased rates of major systemic and vascular comorbidity and substantially higher mortality. Results should be interpreted with caution because of differences in test strategies for COVID-19 and influenza, use of aggregated data, the limited 30-day follow-up and the possibility for changing mortality rates as the pandemic unfolds. However, the true COVID-19 mortality may even be higher than the stated 3.0 to 5.5-fold increase, owing to more extensive testing for COVID-19.

This dataset shows the number of hospital admissions for influenza-like illness, pneumonia, or include ICD-10-CM code (U07.1) for 2019 novel coronavirus. Influenza-like illness is defined as a mention of either: fever and cough, fever and sore throat, fever and shortness of breath or difficulty breathing, or influenza. Patients whose ICD-10-CM code was subsequently assigned with only an ICD-10-CM code for influenza are excluded. Pneumonia is defined as mention or diagnosis of pneumonia. Baseline data represents the average number of people with COVID-19-like illness who are admitted to the hospital during this time of year based on historical counts. The average is based on the daily avg from the rolling same week (same day +/- 3 days) from the prior 3 years. Percent change data represents the change in count of people admitted compared to the previous day. Data sources include all hospital admissions from emergency department visits in NYC. Data are collected electronically and transmitted to the NYC Health Department hourly. This dataset is updated daily. All identifying health information is excluded from the dataset.

Data is from the California Department of Public Health (CDPH) Respiratory Virus Weekly Report.

The report is updated each Friday.

Laboratory surveillance data: California laboratories report SARS-CoV-2 test results to CDPH through electronic laboratory reporting. Los Angeles County SARS-CoV-2 lab data has a 7-day reporting lag. Test positivity is calculated using SARS-CoV-2 lab tests that has a specimen collection date reported during a given week.

Laboratory surveillance for influenza, respiratory syncytial virus (RSV), and other respiratory viruses (parainfluenza types 1-4, human metapneumovirus, non-SARS-CoV-2 coronaviruses, adenovirus, enterovirus/rhinovirus) involves the use of data from clinical sentinel laboratories (hospital, academic or private) located throughout California. Specimens for testing are collected from patients in healthcare settings and do not reflect all testing for influenza, respiratory syncytial virus, and other respiratory viruses in California. These laboratories report the number of laboratory-confirmed influenza, respiratory syncytial virus, and other respiratory virus detections and isolations, and the total number of specimens tested by virus type on a weekly basis.

Test positivity for a given week is calculated by dividing the number of positive COVID-19, influenza, RSV, or other respiratory virus results by the total number of specimens tested for that virus. Weekly laboratory surveillance data are defined as Sunday through Saturday.

Hospitalization data: Data on COVID-19 and influenza hospital admissions are from Centers for Disease Control and Prevention’s (CDC) National Healthcare Safety Network (NHSN) Hospitalization dataset. The requirement to report COVID-19 and influenza-associated hospitalizations was effective November 1, 2024. CDPH pulls NHSN data from the CDC on the Wednesday prior to the publication of the report. Results may differ depending on which day data are pulled. Admission rates are calculated using population estimates from the P-3: Complete State and County Projections Dataset provided by the State of California Department of Finance (https://dof.ca.gov/forecasting/demographics/projections/). Reported weekly admission rates for the entire season use the population estimates for the year the season started. For more information on NHSN data including the protocol and data collection information, see the CDC NHSN webpage (https://www.cdc.gov/nhsn/index.html).

CDPH collaborates with Northern California Kaiser Permanente (NCKP) to monitor trends in RSV admissions. The percentage of RSV admissions is calculated by dividing the number of RSV-related admissions by the total number of admissions during the same period. Admissions for pregnancy, labor and delivery, birth, and outpatient procedures are not included in total number of admissions. These admissions serve as a proxy for RSV activity and do not necessarily represent laboratory confirmed hospitalizations for RSV infections; NCKP members are not representative of all Californians.

Weekly hospitalization data are defined as Sunday through Saturday.

Death certificate data: CDPH receives weekly year-to-date dynamic data on deaths occurring in California from the CDPH Center for Health Statistics and Informatics. These data are limited to deaths occurring among California residents and are analyzed to identify influenza, respiratory syncytial virus, and COVID-19-coded deaths. These deaths are not necessarily laboratory-confirmed and are an underestimate of all influenza, respiratory syncytial virus, and COVID-19-associated deaths in California. Weekly death data are defined as Sunday through Saturday.

Wastewater data: This dataset represents statewide weekly SARS-CoV-2 wastewater summary values. SARS-CoV-2 wastewater concentrations from all sites in California are combined into a single, statewide, unit-less summary value for each week, using a method for data transformation and aggregation developed by the CDC National Wastewater Surveillance System (NWSS). Please see the CDC NWSS data methods page for a description of how these summary values are calculated. Weekly wastewater data are defined as Sunday through Saturday.

Note: After May 3, 2024, this dataset will no longer be updated because hospitals are no longer required to report data on COVID-19 hospital admissions, and hospital capacity and occupancy data, to HHS through CDC’s National Healthcare Safety Network. The related CDC COVID Data Tracker site was revised or retired on May 10, 2023.

This dataset represents daily COVID-19 hospitalization data and metrics aggregated to national, state/territory, and regional levels. COVID-19 hospitalization data are reported to CDC’s National Healthcare Safety Network, which monitors national and local trends in healthcare system stress, capacity, and community disease levels for approximately 6,000 hospitals in the United States. Data reported by hospitals to NHSN and included in this dataset represent aggregated counts and include metrics capturing information specific to COVID-19 hospital admissions, and inpatient and ICU bed capacity occupancy.

Reporting information:

• As of December 15, 2022, COVID-19 hospital data are required to be reported to NHSN, which monitors national and local trends in healthcare system stress, capacity, and community disease levels for approximately 6,000 hospitals in the United States. Data reported by hospitals to NHSN represent aggregated counts and include metrics capturing information specific to hospital capacity, occupancy, hospitalizations, and admissions. Prior to December 15, 2022, hospitals reported data directly to the U.S. Department of Health and Human Services (HHS) or via a state submission for collection in the HHS Unified Hospital Data Surveillance System (UHDSS).
• While CDC reviews these data for errors and corrects those found, some reporting errors might still exist within the data. To minimize errors and inconsistencies in data reported, CDC removes outliers before calculating the metrics. CDC and partners work with reporters to correct these errors and update the data in subsequent weeks.
• Many hospital subtypes, including acute care and critical access hospitals, as well as Veterans Administration, Defense Health Agency, and Indian Health Service hospitals, are included in the metric calculations provided in this report. Psychiatric, rehabilitation, and religious non-medical hospital types are excluded from calculations.
• Data are aggregated and displayed for hospitals with the same Centers for Medicare and Medicaid Services (CMS) Certification Number (CCN), which are assigned by CMS to counties based on the CMS Provider of Services files.
• Full details on COVID-19 hospital data reporting guidance can be found here: https://www.hhs.gov/sites/default/files/covid-19-faqs-hospitals-hospital-laboratory-acute-care-facility-data-reporting.pdf

Metric details:

• Time Period: timeseries data will update weekly on Mondays as soon as they are reviewed and verified, usually before 8 pm ET. Updates will occur the following day when reporting coincides with a federal holiday. Note: Weekly updates might be delayed due to delays in reporting. All data are provisional. Because these provisional counts are subject to change, including updates to data reported previously, adjustments can occur. Data may be updated since original publication due to delays in reporting (to account for data received after a given Thursday publication) or data quality corrections.
• New COVID-19 Hospital Admissions (count): Number of new admissions of patients with laboratory-confirmed COVID-19 in the previous week (including both adult and pediatric admissions) in the entire jurisdiction.
• New COVID-19 Hospital Admissions (7-Day Average): 7-day average of new admissions of patients with laboratory-confirmed COVID-19 in the previous week (including both adult and pediatric admissions) in the entire jurisdiction.
• Cumulative COVID-19 Hospital Admissions: Cumulative total number of admissions of patients with laboratory-confirmed COVID-19 (including both adult and pediatric admissions) in the entire jurisdiction since August 1, 2020.
• Cumulative COVID-19 Hospital Admissions Rate: Cumulative total number of admissions of patients with laboratory-confirmed COVID-19 (including both adult and pediatric admissions) in the entire jurisdiction since August 1, 2020 divided by 2019 intercensal population estimate for that jurisdiction multiplied by 100,000.
• New COVID-19 Hospital Admissions Rate (7-day average) percent change from prior week: Percent change in the 7-day average new admissions of patients with laboratory-confirmed COVID-19 per 100,000 population compared with the prior week.
• New COVID-19 Hospital Admissions (7-Day Total): 7-day total number of new admissions of patients with laboratory-confirmed COVID-19 (including both adult and pediatric admissions) in the entire jurisdiction.
• New COVID-19 Hospital Admissions Rate (7-Day Total): 7-day total number of new admissions of patients with laboratory-confirmed COVID-19 (including both adult and pediatric admissions) for the entire jurisdiction divided by 2019 intercensal population estimate for that jurisdiction multiplied by 100,000.
• Total Hospitalized COVID-19 Patients: 7-day total number of patients currently hospitalized with laboratory-confirmed COVID-19 (including both adult and pediatric patients) for the entire jurisdiction.
• Total Hospitalized COVID-19 Patients (7-Day Average): 7-day average of the number of patients currently hospitalized with laboratory-confirmed COVID-19 (including both adult and pediatric patients) for the entire jurisdiction.
• COVID-19 Inpatient Bed Occupancy (7-Day Average): Percentage of all staffed inpatient beds occupied by patients with laboratory-confirmed COVID-19 (including both adult and pediatric patients) within the entire jurisdiction is calculated as an average of valid daily values within the past 7 days (e.g., if only three valid values, the average of those three is taken). Averages are separately calculated for the daily numerators (patients hospitalized with confirmed COVID-19) and denominators (staffed inpatient beds). The average percentage can then be taken as the ratio of these two values for the entire jurisdiction.
• COVID-19 Inpatient Bed Occupancy absolute change from prior week: The absolute change in the percent of staffed inpatient beds occupied by patients with laboratory-confirmed COVID-19 represents the week-over-week absolute difference between the 7-day average occupancy of patients with confirmed COVID-19 in staffed inpatient beds in the past 7 days, compared with the prior week, in the entire jurisdiction.
• COVID-19 ICU Bed Occupancy (7-Day Average): Percentage of all staffed inpatient beds occupied by adult patients with confirmed COVID-19 within the entire jurisdiction is calculated as a 7-day average of valid daily values within the past 7 days (e.g., if only three valid values, the average of those three is taken). Averages are separately calculated for the daily numerators (adult patients hospitalized with confirmed COVID-19) and denominators (staffed adult ICU beds). The average percentage can then be taken as the ratio of these two values for the entire jurisdiction.
• COVID-19 ICU Bed Occupancy absolute change from prior week: The absolute change in the percent of staffed ICU beds occupied by patients with laboratory-confirmed COVID-19 represents the week-over-week absolute difference between the average occupancy of patients with confirmed COVID-19 in staffed adult ICU beds for the past 7 days, compared with the prior week, in the in the entire jurisdiction.

Notes: October 27, 2023: Due to a data processing error, reported values for avg_percent_inpatient_beds_occupied_covid_confirmed will appear lower than previously reported values by an average difference of less than 1%. Therefore, previously reported values for avg_percent_inpatient_beds_occupied_covid_confirmed may have been overestimated and should be interpreted with caution.

October 27, 2023: Due to a data processing error, reported values for abs_chg_avg_percent_inpatient_beds_occupied_covid_confirmed will differ from previously reported values by an average absolute difference of less than 1%. Therefore, previously reported values for abs_chg_avg_percent_inpatient_beds_occupied_covid_confirmed should be interpreted with caution.

December 29, 2023: Hospitalization data reported to CDC’s National Healthcare Safety Network (NHSN) through December 23, 2023, should be interpreted with caution due to potential reporting delays that are impacted by Christmas and New Years holidays. As a result, metrics including new hospital admissions for COVID-19 and influenza and hospital occupancy may be underestimated for the week ending December 23, 2023.

January 5, 2024: Hospitalization data reported to CDC’s National Healthcare Safety Network (NHSN) through December 30, 2023 should be interpreted with caution due to potential reporting delays that are impacted by Christmas and New Years holidays. As a result, metrics including new hospital admissions for COVID-19 and influenza and hospital occupancy may be underestimated for the week ending December 30, 2023.

Data is from the California Department of Public Health (CDPH) Respiratory Virus Weekly Report. The report is updated each Friday. Laboratory surveillance data: California laboratories report SARS-CoV-2 test results to CDPH through electronic laboratory reporting. Los Angeles County SARS-CoV-2 lab data has a 7-day reporting lag. Test positivity is calculated using SARS-CoV-2 lab tests that has a specimen collection date reported during a given week. Laboratory surveillance for influenza, respiratory syncytial virus (RSV), and other respiratory viruses (parainfluenza types 1-4, human metapneumovirus, non-SARS-CoV-2 coronaviruses, adenovirus, enterovirus/rhinovirus) involves the use of data from clinical sentinel laboratories (hospital, academic or private) located throughout California. Specimens for testing are collected from patients in healthcare settings and do not reflect all testing for influenza, respiratory syncytial virus, and other respiratory viruses in California. These laboratories report the number of laboratory-confirmed influenza, respiratory syncytial virus, and other respiratory virus detections and isolations, and the total number of specimens tested by virus type on a weekly basis. Test positivity for a given week is calculated by dividing the number of positive COVID-19, influenza, RSV, or other respiratory virus results by the total number of specimens tested for that virus. Weekly laboratory surveillance data are defined as Sunday through Saturday. Hospitalization data: Data on COVID-19 and influenza hospital admissions are from Centers for Disease Control and Prevention’s (CDC) National Healthcare Safety Network (NHSN) Hospitalization dataset. The requirement to report COVID-19 and influenza-associated hospitalizations was effective November 1, 2024. CDPH pulls NHSN data from the CDC on the Wednesday prior to the publication of the report. Results may differ depending on which day data are pulled. Admission rates are calculated using population estimates from the P-3: Complete State and County Projections Dataset provided by the State of California Department of Finance (https://res1dofd-o-tcad-o-tgov.vcapture.xyz/forecasting/demographics/projections/). Reported weekly admission rates for the entire season use the population estimates for the year the season started. For more information on NHSN data including the protocol and data collection information, see the CDC NHSN webpage (https://res1wwwd-o-tcdcd-o-tgov.vcapture.xyz/nhsn/index.html). CDPH collaborates with Northern California Kaiser Permanente (NCKP) to monitor trends in RSV admissions. The percentage of RSV admissions is calculated by dividing the number of RSV-related admissions by the total number of admissions during the same period. Admissions for pregnancy, labor and delivery, birth, and outpatient procedures are not included in total number of admissions. These admissions serve as a proxy for RSV activity and do not necessarily represent laboratory confirmed hospitalizations for RSV infections; NCKP members are not representative of all Californians. Weekly hospitalization data are defined as Sunday through Saturday. Death certificate data: CDPH receives weekly year-to-date dynamic data on deaths occurring in California from the CDPH Center for Health Statistics and Informatics. These data are limited to deaths occurring among California residents and are analyzed to identify influenza, respiratory syncytial virus, and COVID-19-coded deaths. These deaths are not necessarily laboratory-confirmed and are an underestimate of all influenza, respiratory syncytial virus, and COVID-19-associated deaths in California. Weekly death data are defined as Sunday through Saturday. Wastewater data: This dataset represents statewide weekly SARS-CoV-2 wastewater summary values. SARS-CoV-2 wastewater concentrations from all sites in California are combined into a single, statewide, unit-less summary value for each week, using a method for data transformation and aggregation developed by the CDC National Wastewater Surveillance System (NWSS). Please see the CDC NWSS data methods page for a description of how these summary values are calculated. Weekly wastewater data are defined as Sunday through Saturday.

Rank, number of deaths, percentage of deaths, and age-specific mortality rates for the leading causes of death, by age group and sex, 2000 to most recent year.

This publication was archived on 12 October 2023. Please see the Viral Respiratory Diseases (Including Influenza and COVID-19) in Scotland publication for the latest data. This dataset provides information on number of new daily confirmed cases, negative cases, deaths, testing by NHS Labs (Pillar 1) and UK Government (Pillar 2), new hospital admissions, new ICU admissions, hospital and ICU bed occupancy from novel coronavirus (COVID-19) in Scotland, including cumulative totals and population rates at Scotland, NHS Board and Council Area levels (where possible). Seven day positive cases and population rates are also presented by Neighbourhood Area (Intermediate Zone 2011). Information on how PHS publish small are COVID figures is available on the PHS website. Information on demographic characteristics (age, sex, deprivation) of confirmed novel coronavirus (COVID-19) cases, as well as trend data regarding the wider impact of the virus on the healthcare system is provided in this publication. Data includes information on primary care out of hours consultations, respiratory calls made to NHS24, contact with COVID-19 Hubs and Assessment Centres, incidents received by Scottish Ambulance Services (SAS), as well as COVID-19 related hospital admissions and admissions to ICU (Intensive Care Unit). Further data on the wider impact of the COVID-19 response, focusing on hospital admissions, unscheduled care and volume of calls to NHS24, is available on the COVID-19 Wider Impact Dashboard. Novel coronavirus (COVID-19) is a new strain of coronavirus first identified in Wuhan, China. Clinical presentation may range from mild-to-moderate illness to pneumonia or severe acute respiratory infection. COVID-19 was declared a pandemic by the World Health Organisation on 12 March 2020. We now have spread of COVID-19 within communities in the UK. Public Health Scotland no longer reports the number of COVID-19 deaths within 28 days of a first positive test from 2nd June 2022. Please refer to NRS death certificate data as the single source for COVID-19 deaths data in Scotland. In the process of updating the hospital admissions reporting to include reinfections, we have had to review existing methodology. In order to provide the best possible linkage of COVID-19 cases to hospital admissions, each admission record is required to have a discharge date, to allow us to better match the most appropriate COVID positive episode details to an admission. This means that in cases where the discharge date is missing (either due to the patient still being treated, delays in discharge information being submitted or data quality issues), it has to be estimated. Estimating a discharge date for historic records means that the average stay for those with missing dates is reduced, and fewer stays overlap with records of positive tests. The result of these changes has meant that approximately 1,200 historic COVID admissions have been removed due to improvements in methodology to handle missing discharge dates, while approximately 820 have been added to the cumulative total with the inclusion of reinfections. COVID-19 hospital admissions are now identified as the following: A patient's first positive PCR or LFD test of the episode of infection (including reinfections at 90 days or more) for COVID-19 up to 14 days prior to admission to hospital, on the day of their admission or during their stay in hospital. If a patient's first positive PCR or LFD test of the episode of infection is after their date of discharge from hospital, they are not included in the analysis. Information on COVID-19, including stay at home advice for people who are self-isolating and their households, can be found on NHS Inform. Data visualisation of Scottish COVID-19 cases is available on the Public Health Scotland - Covid 19 Scotland dashboard. Further information on coronavirus in Scotland is available on the Scottish Government - Coronavirus in Scotland page, where further breakdown of past coronavirus data has also been published.

This dataset is no longer updated, find vaccination data here From 24 March 2022, Public Health Scotland (PHS) began reporting the number of people who have received a fourth dose of Covid-19 vaccination. Vaccine uptake statistics among care home residents and those who are severely immunosuppressed will be reported initially. PHS will include further updates as the Spring/Summer vaccination programme rolls out. In addition, as part of our continuous review of reporting, PHS made some changes to vaccine uptake statistics. From 24 March 2022, the deceased and those who no longer live in Scotland are no longer be included in vaccine uptake statistics. Historic trend data have been updated to take into account this new methodology for all apart from the Daily Trends by JCVI Priority Group table (more details about the data in this table are below). Scotland level data for all vaccinations administered (i.e. including those who have since died or moved from Scotland) are still available in the Daily Trend of All Vaccinations Delivered in Scotland table. Also from 24 March 2022, Dose 3/Booster doses are termed "Dose 3". To allow new data to be fully processed and available at 14:00, the Daily COVID-19 in Scotland and COVID-19 Vaccination in Scotland datasets will be temporarily unavailable from 12:45 to 14:00. During this window, the datasets will not be visible and any queries made to these datasets will return a 404 - Not found error. At all other times the datasets will be available in full as usual. PHS reviewed the JCVI priority group uptake figures from 18 November 2021, specifically how we derive the numerator and the denominator. The rational for the change is to ensure we report on most up to date living population for each group. For this, the list of individuals in each cohort has been refreshed to be more current. We have also removed individuals who have since died to reflect the current living population. From the 24 March 2022 those who are no longer living in Scotland have also been removed from the numerator and denominator for JCVI priority group uptake figures. This means all the JCVI cohorts and populations have changed for both numerator and denominators on these two dates and care should be taken when interpreting trends. On 08 December 2020, a Coronavirus (COVID-19) vaccine developed by Pfizer BioNTech (Comirnaty) was first used in the UK as part of national immunisation programmes. The AstraZeneca (Spikevax) vaccine was also approved for use in the national programme, and rollout of this vaccine began on 04 January 2021. Moderna (Vaxzevria) vaccine was approved for use on 8 January 2021 and rollout of this vaccine began on 07 April 2021. These vaccines have met strict standards of safety, quality and effectiveness set out by the independent Medicines and Healthcare Products Regulatory Agency (MHRA). Those giving the vaccine to others were the first to receive the vaccination. In the first phase of the programme, NHS Scotland followed the independent advice received from the Joint Committee on Vaccination and Immunisation (JCVI) and prioritised delivery of the vaccine to those with the greatest clinical need, in line with the recommended order of prioritisation. For booster vaccinations a similar approach has been adopted. Definitions used in the vaccine uptake by JCVI priority group resource can be found in the JCVI Priority Group Definitions table. Individuals can appear in more than one JCVI priority group. This dataset provides information on daily number of COVID vaccinations in Scotland. Data on the total number of vaccinations in Scotland is presented by day administered and vaccine type, by age group, by sex, by non-age cohorts and by geographies (NHS Board and Local Authority). As the population in the cohorts can change with time, these will be refined when updated data are available. Additional data sources relating to this topic area are provided in the Links section of the Metadata below. Data visualisation and additional notes are available on the Public Health Scotland - Covid 19 Scotland dashboard.

The dataset shows the 7-day median of the RNA copies of the specified virus per day and 100’000 people in the wastewater treatment plant (ARA) Basel as well as the 7-day median of the corresponding case numbers. The data set is usually updated on Tuesdays with the data until the previous Sunday. ProRheno AG (operator of ARA Basel) takes a 24h sample of the raw waste water, which is examined for RNA of the specified viruses by the Cantonal Laboratory Basel-Stadt (KL BS). The measurement methodology has not been changed since the beginning of the monitoring: see publication https://smw.ch/index.php/smw/article/view/3226. The plausibility of the values is continuously checked against internal quality parameters. The study area comprises the catchment area of the ARA Basel, which consists mainly of the canton of Basel-Stadt as well as the municipalities of Allschwil, Binningen, Birsfelden, Bottmingen, Oberwil and Schönenbuch (all Canton Baselland). Until the end of June 2023, the measured values of the KL BS were also presented on the wastewater dashboard of the BAG Covid-19 Switzerland | Coronavirus | Dashboard (https://www.covid19.admin.ch/de/epidemiologic/waste-water?wasteWaterFacility=270101). As of July 2023, the measured values of the EAWAG SARS-CoV2 in wastewater – Eawag (https://www.eawag.ch/de/abteilung/sww/projekte/sars-cov2-im-abwasser/) will be published on this page, which also examines the raw wastewater of ARA Basel. The methods used by KL BS and EAWAG are very similar but not identical. 29.4. to 1.8.2022 (except 1.6.2022 and 5.6.2022) and 30.5.2023 to 3.9.2023 no waste water samples were tested for influenza and RSV.Case numbers correspond to the number of confirmed and reported cases of infections in the catchment area of the ARA Basel.Interpretation of curvesThe monitoring of viruses in wastewater is primarily about identifying trends (especially, of course, the increase of a circulating virus). It is not possible to derive a certain number of cases or the severity of an infection. A comparison of the curve rash (height of peaks) at different times is hardly possible, because different virus variants lead to different amounts of virus per case. Different virus variants can also affect the symptoms, so that, for example, infections in humans run without a trace, but nevertheless viruses are released into the wastewater. Click here for the dashboard

The California Department of Public Health (CDPH) is coordinating with wastewater utilities, local health departments, academic researchers, and laboratories in California on wastewater surveillance for infectious disease pathogens of interest to public health (such as SARS-CoV-2, the virus causing COVID-19, influenza, respiratory syncytial virus (RSV), mpox, and norovirus). Data collected from this network of participants, called the California Surveillance of Wastewaters (Cal-SuWers) Network, are submitted to the U.S. Centers for Disease Control and Prevention (CDC) National Wastewater Surveillance System (NWSS).

Collecting and analyzing wastewater samples for the presence of, and amount of (concentration), a specified pathogen target can help inform public health about circulation of that infectious disease within a community. Data from wastewater testing do not replace existing public health surveillance systems but complement them. While wastewater surveillance cannot determine the exact number of infected persons in the area being monitored, it can provide overall trends of pathogen concentration within that community.

Please note that data included in the Cal-SuWers Network and available here originate from multiple programs and laboratories. Methodologies for producing wastewater data are not currently standardized, and analyses, comparisons, and aggregations should be done with caution. Wastewater is a complex environmental sample and inherent variability in measured concentrations is expected due to environmental variability, day-to-day differences in sewershed and population dynamics, differences in the amount of shedding between people and pathogens, and laboratory and sampling variability. Please see the CDPH Cal-SuWers, CDC NWSS, and CDC Public Health interpretation and Use of Wastewater Surveillance data webpages for more information.

Historical wastewater data can be found here.